Outlook Therapeutics shares rise 1.65% intraday after requesting a Type A meeting with the FDA to discuss ONS-5010.

Outlook Therapeutics, Inc. rose 1.65% in intraday trading, with the company requesting a Type A Meeting with the FDA to discuss the complete response letter regarding the biologics license application for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. The FDA acknowledged that the NORSE TWO pivotal trial met its safety and efficacy endpoints, but recommended confirmatory evidence.